Related Experiment Video
Updated: Jan 25, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Estimates of the future burden of cancer attributable to infections in Canada
Karena D Volesky1, Mariam El-Zein2, Eduardo L Franco1
1Gerald Bronfman Department of Oncology, Division of Cancer Epidemiology, McGill University, Montréal, Québec, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada.
Abstract:
More than 7000 incident cancers diagnosed in Canada in 2015 were attributable to infections. The future infection-associated cancer burden can be lowered by reducing the prevalence of major cancer-causing infections; hepatitis B virus (HBV), hepatitis C virus (HCV), Helicobacter pylori (H. pylori) and human papillomavirus (HPV). We modeled the future impact of (1) 10%, 25%, and 50% relative reductions in the prevalence of HBV, HCV and H. pylori and (2) different school-based HPV vaccination coverage levels (lower, current, higher) on Canadian cancer incidence by the year 2042. We modeled counterfactual reductions in HBV, HCV and H. pylori prevalence in 2018, assuming a latency period of 15-years, to estimate the impact on cancer incidence starting in 2033. The number of HPV-attributable cancers among vaccinated cohorts was a function of pre-2018 vaccine coverage levels and the 2018 counterfactuals. A 50% counterfactual reduction in the prevalence of HBV, HCV and H. pylori could prevent an estimated 10,585 cancers from 2018 to 2042; a 25% reduction could prevent 5293 cancers and a 10% reduction could prevent 2117 cancers. Assuming continuity of current estimated country-wide HPV vaccine coverage, 3977 anogenital and 1073 head and neck cancers could be prevented from 2018 to 2042, whereas vaccine coverage of 80% in girls and boys could prevent an additional 311 cancers. Almost 16,000 cancers could be prevented in Canada from 2018 to 2042 with a 50% relative reduction in HBV, HCV and H. pylori prevalence and 80% HPV vaccine coverage of girls and boys.
Insights
Reducing infections like hepatitis B, C, H. pylori, and HPV can prevent thousands of future cancers in Canada. Increased HPV vaccination and infection control show significant potential for cancer burden reduction.
Area of Science:
- Public Health
- Epidemiology
- Infectious Disease Prevention
Background:
- In 2015, over 7000 incident cancers in Canada were linked to infections.
- Key infection-causing agents include hepatitis B virus (HBV), hepatitis C virus (HCV), Helicobacter pylori (H. pylori), and human papillomavirus (HPV).
- Reducing the prevalence of these infections can lower the future burden of associated cancers.
Purpose of the Study:
- To model the future impact of reducing HBV, HCV, and H. pylori prevalence on cancer incidence.
- To assess the effect of varying school-based HPV vaccination coverage levels on cancer prevention.
- To estimate the total number of cancers preventable by 2042 through these interventions.
Main Methods:
- Modeled counterfactual reductions in HBV, HCV, and H. pylori prevalence in 2018.
- Assumed a 15-year latency period to estimate cancer incidence from 2033 onwards.
- Calculated HPV-attributable cancers based on pre-2018 vaccination coverage and 2018 counterfactuals.
Main Results:
- A 50% reduction in HBV, HCV, and H. pylori prevalence could prevent an estimated 10,585 cancers by 2042.
- Current HPV vaccination coverage could prevent 3977 anogenital and 1073 head and neck cancers by 2042.
- Achieving 80% HPV vaccination coverage in both genders could prevent an additional 311 cancers.
Conclusions:
- Significant cancer prevention is achievable through targeted reductions in infection prevalence.
- Enhanced HPV vaccination programs are crucial for preventing anogenital and head and neck cancers.
- A combined strategy of infection control and high HPV vaccination coverage could prevent nearly 16,000 cancers by 2042.
More Related Videos
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
07:33Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
Related Concept Videos
Fundamental Attribution Error
Attribution Theory
Attribution
Personal Choice and Fate Attributions
What are Estimates?
The estimate for the mean of a sample is denoted by ͞x, whereas the mean of the population is designated as μ. Further, parameters such...
Theory of Attribution I: Correspondent Inference Theory